Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies’ pipeline candidates. The joint invention aims to revolutionize transdermal release of “difficult-to-formulate” compounds…
Tetra Pharm Technologies Advances CB1 Antagonist TPT0701 for Appetite Suppression into Preclinical Testing
Following the successful filing of the Intellectual Property (IP) for its applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies is moving forward with its appetite suppression supplement, TPT0701. Modulation of the endocannabinoid system has long been recognized…
